Physician profile
Brad E Fuller
NPI 1104068949
$5,094.44
in general payments reported to CMS, 2019-2025
30 companies · $671 in 2025
The $671 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $436 · 2021: $603 · 2022: $708 · 2023: $1,172 · 2024: $1,069 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482 · Consulting Fee: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.33 |
| Consulting Fee | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $874.92 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $555.31 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $453.00 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $447.82 | 2019-2025 | Bexsero |
| Incyte Corporation | $430.00 | 2023 | |
| Pfizer INC. | $236.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $226.65 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $211.71 | 2020-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $204.45 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $201.84 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $188.62 | 2019-2025 | Doc Band |
| Kaleo, INC. | $175.86 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $172.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $105.83 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $92.89 | 2025 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $85.67 | 2019-2025 | Relexxii |
| Astrazeneca Pharmaceuticals Lp | $51.47 | 2024 | Flumist Quadrivalent |
| Organon LLC | $42.61 | 2025 | |
| Verrica Pharmaceuticals INC. | $41.23 | 2025 | Ycanth |
| Adlon Therapeutics L.P. | $35.26 | 2019-2021 | |
| Genentech USA, INC. | $34.57 | 2020-2021 | |
| Kyowa Kirin, INC. | $33.62 | 2023-2024 | Crysvita |
| Exeltis, USA INC. | $32.98 | 2023 | Slynd |
| Teva Pharmaceuticals USA, INC. | $31.11 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.32 | 2019-2023 | Strensiq |
| Acadia Pharmaceuticals INC | $22.41 | 2025 | Daybue |
| Shire North American Group INC | $21.20 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.07 | 2024 | Crysvita |
| Seqirus USA INC | $18.36 | 2025 | Flucelvax |
| Amneal Pharmaceuticals LLC | $17.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.